‘I was shocked’: Con­tro­ver­sy brews at Emory af­ter promi­nent Chi­nese neu­ro­sci­en­tists are oust­ed over dis­clo­sure is­sues

It’s what Chi­nese sci­en­tists work­ing in the US have been dread­ing since MD An­der­son oust­ed three of its Asian fac­ul­ty mem­bers fol­low­ing NIH-di­rect­ed in­ves­ti­ga­tions: A sec­ond pres­ti­gious in­sti­tu­tion has closed down a promi­nent lab and ter­mi­nat­ed the two Chi­na-born re­searchers head­ing the lab.

The news, com­ing out of Emory Uni­ver­si­ty, is once again stir­ring up in­dig­na­tion, be­wil­der­ment and anx­i­ety among Chi­nese aca­d­e­mics and ne­ti­zens alike, not least be­cause the oust­ed pro­fes­sors have gone pub­lic with their side of the sto­ry, ques­tion­ing how the school han­dled the fir­ing, dis­put­ing ac­cu­sa­tions and ex­press­ing their wor­ry. As a con­se­quence, sev­er­al post­docs from Chi­na work­ing in their lab have al­so been asked to leave the coun­try.

Xi­ao­jiang Li Emory

Xi­ao­jiang Li and Shi­hua Li were 23-year vet­er­ans of Emory and not­ed neu­ro­sci­en­tists spe­cial­iz­ing in Hunt­ing­ton’s dis­ease. The mar­ried cou­ple, who are now US cit­i­zens, joint­ly ran a lab at Emory that re­cent­ly cre­at­ed a pig mod­el for the ge­net­ic ail­ment that they say rep­re­sents bet­ter test­ing grounds for new treat­ments. Last April, they pub­lished this find­ing in Cell in col­lab­o­ra­tion with Ji­nan Uni­ver­si­ty and the Chi­nese Acad­e­my of Sci­ences in Guangzhou.

Xi­ao­jiang Li was giv­ing a speech at Ji­nan, where he is a part-time pro­fes­sor, when The At­lanta Jour­nal-Con­sti­tu­tion re­port­ed on May 23 that Emory has fired two re­searchers for fail­ing to dis­close fund­ing from and re­search ties with Chi­nese en­ti­ties.

The no­ti­fi­ca­tion ar­rived one week ear­li­er, he told the Chi­nese blog Zhishifen­zi, and on the same day, his lab was shut down. The grad­u­ate stu­dents and post­docs at the scene were de­mand­ed to stop their ex­per­i­ments, va­cate the lab and at­tend in­ter­views with “strangers in suits,” Zhishifen­zi re­port­ed based on con­ver­sa­tions with wit­ness­es.

On May 24, Xi­ao­jiang Li bat back at Emory through a state­ment to Sci­ence, in which he claimed to have dis­closed his Chi­nese re­search ac­tiv­i­ty to the uni­ver­si­ty since 2012 when he be­gan work­ing on non-hu­man pri­mate re­search in Chi­na and co­op­er­at­ed with its in­ves­ti­ga­tion dat­ing back to No­vem­ber 2018.

Shi­hua Li Emory

“I was shocked that Emory Uni­ver­si­ty would ter­mi­nate a tenured pro­fes­sor in such an un­usu­al and abrupt fash­ion and close our com­bined lab con­sist­ing of a num­ber of grad­u­ates and post­doc­tor­al trainees with­out giv­ing me spe­cif­ic de­tails for the rea­sons be­hind my ter­mi­na­tion,” he said, adding he’s re­quest­ed a copy of the in­ves­ti­ga­tion.

As in the case with MD An­der­son, Emory said it ini­ti­at­ed its own in­ves­ti­ga­tions af­ter the NIH brought sus­pi­cion of mis­con­duct to their at­ten­tion.

The probe at the pres­ti­gious Hous­ton re­search hos­pi­tal in­volved a to­tal of five re­searchers, with con­cerns span­ning vi­o­la­tions of peer re­view con­fi­den­tial­i­ty as well as fail­ure to dis­close for­eign sources of fund­ing and po­ten­tial con­flicts of in­ter­est. Au­thor­i­ties made the call to purge three of them, cleared an­oth­er of sanc­tions, and are still look­ing in­to the last.

Amid a trade war with Chi­na and in­creased na­tion­al vig­i­lance re­gard­ing aca­d­e­m­ic es­pi­onage, the NIH be­gan warn­ing grantee in­sti­tu­tions about sci­en­tists with for­eign ties in 2018, prompt­ing at least 55 to launch their own probes.

“(W)e re­mind uni­ver­si­ties to look close­ly at their or­ga­ni­za­tions to mit­i­gate un­scrupu­lous prac­tices by for­eign en­ti­ties that aim to cap­i­tal­ize on the col­lab­o­ra­tive na­ture of the U.S. bio­med­ical en­ter­prise,” an NIH spokesper­son told End­points News in the wake of MD An­der­son’s ac­tions, which marked the pub­lic in­stance of a US bio­med­ical in­sti­tu­tion sanc­tion­ing its own re­searchers for al­leged threats of for­eign in­flu­ence.

The fate of Xi­ao­jiang Li’s six NIH-fund­ed projects re­mains un­known, as does those of his post­doc re­searchers be­ing force­ful­ly repa­tri­at­ed (one of whom is preg­nant), Xi­ao­jiang Li said to Sci­ence. The pres­i­dent of Ji­nan has pub­licly pledged to host the Li’s en­tire team and pro­vide them with the fa­cil­i­ties and equip­ment to con­tin­ue their work.


Im­age: Emory Uni­ver­si­ty. Shut­ter­stock

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Christian Itin, Autolus CEO (UKBIO19)

Au­to­lus tips its hand, bags $220M as CAR-T show­down with Gilead looms

The first batch of pivotal data on Autolus Therapeutics’ CAR-T is in, and execs are ready to plot a path to market.

With an overall remission rate of 70% at the interim analysis featuring 50 patients, the results set the stage for a BLA filing by the end of 2023, said CEO Christian Itin.

Perhaps more importantly — given that Autolus’ drug, obe-cel, is going after an indication that Gilead’s Tecartus is already approved for — the biotech highlighted “encouraging safety data” in the trial, with a low percentage of patients experiencing severe immune responses.

Dipal Doshi, Entrada Therapeutics CEO

Ver­tex just found the next big ‘trans­for­ma­tive’ thing for the pipeline — at a biotech just down the street

Back in the summer of 2019, when I was covering Vertex’s executive chairman Jeff Leiden’s plans for the pipeline, I picked up on a distinct focus on myotonic dystrophy Type I, or DM1 — one of what Leiden called “two diseases (with DMD) we’re interested in and we continue to look for those assets.”

Today, Leiden’s successor at the helm of Vertex, CEO Reshma Kewalramani, is plunking down $250 million in cash to go the extra mile on DM1. The lion’s share of that is for the upfront, with a small reserve for equity in a deal that lines Vertex up with a neighbor in Seaport that has been rather quietly going at both of Vertex’s early disease targets with preclinical assets.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

WIB22: Am­ber Salz­man had few op­tions when her son was di­ag­nosed with a rare ge­net­ic dis­ease. So she cre­at­ed a bet­ter one

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

Amber Salzman’s life changed on a cold, damp day in Paris over tiny plastic cups of lukewarm tea.

She was meeting with Patrick Aubourg, a French neurologist studying adrenoleukodystrophy, or ALD, a rare genetic condition that causes rapid neurological decline in young boys. It’s a sinister disease that often leads to disability or death within just a few years. Salzman’s nephew was diagnosed at just 6 or 7 years old, and died at the age of 12.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

Ahead of ad­comm, FDA rais­es un­cer­tain­ties on ben­e­fit-risk pro­file of Cy­to­ki­net­ic­s' po­ten­tial heart drug

The FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics’ potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.

The drug, known as omecamtiv mecarbil and in development for more than 15 years, has seen mixed results, with a first Phase III readout from November 2020 hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as key to breaking into the market.

Ab­b­Vie slapped with age dis­crim­i­na­tion law­suit, fol­low­ing oth­er phar­mas

Add AbbVie to the list of pharma companies currently facing age discrimination allegations.

Pennsylvania resident Thomas Hesch filed suit against AbbVie on Wednesday, accusing the company of passing him over for promotions in favor of younger candidates.

Despite 30 years of pharma experience, “Hesch has consistently seen younger, less qualified employees promoted over him,” the complaint states.

Rami Elghandour, Arcellx CEO

Up­dat­ed: Gilead, Ar­cel­lx team up on an­ti-BC­MA CAR-T as biotech touts a 100% re­sponse rate at #ASH22

Gilead and Kite are plunking down big cash to get into the anti-BCMA CAR-T game.

The pair will shell out $225 million in cash upfront and $100 million in equity to Arcellx, Kite announced Friday morning, to develop the biotech’s lead CAR-T program together. Kite will handle commercialization and co-development with Arcellx, and profits in the US will be split 50-50.

Concurrent with the deal, Arcellx revealed its latest cut of data for the program known as CART-ddBCMA, ahead of a full presentation at this weekend’s ASH conference — a 100% response rate among patients getting the therapy. Investors jumped at the dual announcements, sending Arcellx shares $ACLX up more than 25% in Friday’s morning session.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

WIB22: Lead­ing NK cell re­searcher re­flects on roots in Iran, the UK and Texas

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

In a small but widely-cited 11-person study published in NEJM in 2020, seven patients saw signs of their cancer completely go away after getting a new therapy made from natural killer cells. The study was one of the earliest to provide clinical proof that the experimental treatment method had promise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

WIB22: Chas­ing af­ter ever-evolv­ing sci­ence takes a drug hunter across the pond

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

Like many scientists, Fiona Marshall would tell you that she loved the natural world growing up — going to look at crabs running around the beach near her childhood home, pondering about the tides. But one thing about biology, in particular, stood out: It was constantly changing, and changing very quickly.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.